Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci

• Published in: Molecular neurodegeneration Vol. 13; no. 1; pp. 37 - 10
• Main Authors: Sanchez-Contreras, Monica Y, Kouri, Naomi, Cook, Casey N, Serie, Daniel J, Heckman, Michael G, Finch, NiCole A, Caselli, Richard J, Uitti, Ryan J, Wszolek, Zbigniew K, Graff-Radford, Neill, Petrucelli, Leonard, Wang, Li-San, Schellenberg, Gerard D, Dickson, Dennis W, Rademakers, Rosa, Ross, Owen A
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09-07-2018; BioMed Central; BMC
• Subjects: Aged; Aged, 80 and over; Basal ganglia; Bioinformatics; Brain research; Brain stem; Central nervous system diseases; Colorectal cancer; Diencephalon; Disease susceptibility; Dual-Specificity Phosphatases - genetics; Female; Genes; Genetic aspects; Genetic diversity; Genetic Predisposition to Disease - genetics; Genome-wide association studies; Genome-Wide Association Study; Genomes; Genotype; Haplotypes; Heredity; Humans; Male; Medical records; Meta-analysis; Middle Aged; Mitogen-Activated Protein Kinase Phosphatases - genetics; Movement disorders; Mutation; Neurodegenerative diseases; Neuropathology; Oligodendrocyte-myelin glycoprotein; Organic Anion Transporters - genetics; Paralysis; Pathology; Polymorphism, Single Nucleotide; Polypeptides; Progressive supranuclear palsy; Risk factors; Scholarly publishing; Studies; Supranuclear Palsy, Progressive - genetics; Tau protein; United States
• ISSN: 1750-1326; 1750-1326
• DOI: 10.1186/s13024-018-0267-3

Progressive supranuclear palsy (PSP) is a parkinsonian neurodegenerative tauopathy affecting brain regions involved in motor function, including the basal ganglia, diencephalon and brainstem. While PSP is largely considered to be a sporadic disorder, cases with suspected familial inheritance have been identified and the common MAPT H1haplotype is a major genetic risk factor. Due to the relatively low prevalence of PSP, large sample sizes can be difficult to achieve, and this has limited the ability to detect true genetic risk factors at the genome-wide statistical threshold for significance in GWAS data. With this in mind, in this study we genotyped the genetic variants that displayed the strongest degree of association with PSP (P<1E-4) in the previous GWAS in a new cohort of 533 pathologically-confirmed PSP cases and 1172 controls, and performed a combined analysis with the previous GWAS data.
Our findings validate the known association of loci at MAPT, MOBP, EIF2AK3 and STX6 with risk of PSP, and uncover novel associations with SLCO1A2 (rs11568563) and DUSP10 (rs6687758) variants, both of which were classified as non-significant in the original GWAS.
Resolving the genetic architecture of PSP will provide mechanistic insights and nominate candidate genes and pathways for future therapeutic intervention strategies.